Phio Pharmaceuticals Announced The Poster Presentation Of Two Key Preclinical Studies Of Its INTASYL Compound PH-894 At The AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
Portfolio Pulse from Benzinga Newsdesk
Phio Pharmaceuticals has announced the presentation of two key preclinical studies of its INTASYL compound PH-894 at the AACR-NCI-EORTC International Conference. The data shows that melanoma cells treated with PH-894 become more recognizable to immune cells, increasing their potential for elimination. Additionally, PH-894 has demonstrated effectiveness as an antitumor cytotoxic agent.
October 11, 2023 | 11:36 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Phio Pharmaceuticals' INTASYL compound PH-894 has shown promising preclinical results, potentially boosting the company's reputation and investor confidence.
The announcement of promising preclinical data for Phio Pharmaceuticals' INTASYL compound PH-894 could positively impact the company's stock. The data shows the compound's potential in treating melanoma, which could lead to increased investor interest and confidence in the company's research and development capabilities. This could potentially drive the company's stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100